The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-α induced apoptosis

Cell Death and Differentiation

Volumn 5, Issue 2, 1998, Pages 163-171

  Dickinson, Joanne L ^a,c   Norris, Belinda J ^a   Jensen, Poul H ^b   Antalis, Toni M ^a,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b AARHUS UNIVERSITY   (Denmark)

^c ROYAL HOBART HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Apoptosis; Cell death; Plasminogen activator inhibitor; Serpin; Tumor necrosis factor

Indexed keywords

AMINO ACID; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL MEMBRANE; CHICKEN; CROSS LINKING; DELETION MUTANT; HELA CELL; PRIORITY JOURNAL;

GALLUS GALLUS;

EID: 0031817915     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400324     Document Type: Article

References (35)

1. Antalis TM, Clark MA, Barnes T, Lehrbach PR, Devine PL, Schevzov G, Goss NH, Stephens RW and Tolstoshev P (1988) Cloning and expression of a cDNA coding for a human monocyte derived plasminogen activator inhibitor. Proc. Natl. Acad Sci. U.S A. 85: 985-989
2. Antalis TM and Dickinson JL (1992) Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells. Eur. J. Biochem. 205: 203-209
3. Chomcyznski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanade-phenol-chloroform extraction. Anal. Biochem. 162: 156-159
4. Church FC, Pratt CW and Whinna HC (1992) A comparison of three heparin-binding serine proteinase inhibitors. J. Biol Chem. 267: 8795-8801
5. Dickinson JL, Bates EJ, Ferrante A and Antalis TM (1995) Plasminogen activator inhibitor-type 2 inhibits TNFα-induced apoptosis: Evidence for an alternate biological function. J. Biol Chem 270 27894-27904
6. Feinberg AP and Vogelstein B (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132: 6-13
7. Fesus L, Madi A, Balaithy Z, Nemes Z, Szondy Z (1996) Transglutaminase induction by various cell death and apoptosis pathways. Experientia 52(10-11): 942-949
8. Gan H, Newman GW and Remold HG (1995) Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with mycobacterium avium Serovar 4. J. of Immunol. 155: 1304-1315
9. Gentile V, Thomazy V, Piacentini M, Fesus L and Davies PJA (1992) Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts effects on cellular morphology and adhesion. J. Cell. Biol 119: 463-474
10. Jensen PH, Christensen EI, Ebbesen P, Gliemann J and Andreasen PA (1990) Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic chroiocarcinoma cells Cell Reg 1: 1043-1056
11. Jensen PH, Cressey LI, Gjertsen BT, Madsen P, Melgren G, Hokland P, Gliemann J, Døskeland SO, Lanotte M and Vintermyr OK (1994) Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. Brit. J. Cancer. 70: 834-840
12. Jensen PH, Jensen TG, Laug WE, Hager H, Gliemann J and Pepinsky B (1996) The exon 3 encoded sequence of the intracellular serine proteinase inhibitor Plasminogen activator inhibitor-2 (PAI-2) is a protein binding domain. J Biol. Chem. 271: 26892-26899
13. Jensen PH, Lorand L, Ebbesen P and Gliemann J (1993) Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and Factor XIIIa Eur. J. Biochem. 214: 141-146
14. 86 essential for transglutaminase-mediated cross-linking. J. Biol. Chem 269: 15394-15398
15. Jensen PJ Wu Q, Janowitz P, Ando Y and Schechter NM (1995) Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope Exp. Cell Res. 217: 65-71
16. Kiso U, Kaudewitz H, Henschen A, Astedt B, Kruithof EKO and Bachmann F (1988) Determination of intermediates products and cleavage site in the reaction between plasminogen activator inhibitor type-2 and urokinases FEBS Letts. 230 51-56
17. Knight CR, Rees RC and Griffin M (1991) Apoptosis: a potential role for cytosolic transglutaminase and its importance in tumour progression. Biochem. Biophys. Acta 1096: 312-318
18. Kruithof EKO, Baker M and Bunn CL (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2 Blood 86: 4007-4024
19. Kumar S and Baglioni C (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type 2. J Biol Chem 265: 20960-20964
20. Lawrence DA, Berkenpas MB, Palaniappan S and Ginsburg D (1994) Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269: 15223-15228
21. Loebermann H, Tokuoka R, Deisenhofer J and HuberR (1984) Human α1-proteinase inhibitor: Crystal structure analysis of two crystal modifications molecular model and preliminary analysis of the implications for function. J Mol. Biol. 177: 531-556
22. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M and Jensen PJ (1994) Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochem. J. 101: 105-112
23. Radtke KP, Wenz KH and Heimburger N (1990) Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta Evidence for vitronectin/PAI-2 complexes in human placenta extract Biol Chem. Hoppe-Seyler 371: 1119-1127
24. Remold-O'Donnell E (1993) The ovalbumin family of serpin proteins. FEBS Letters 315 (2). 105-108
25. 2-treated rat thymocytes by lipocortin I Biochem Biophys. Res. Comm. 220: 643-647
26. Samia JA, Alexander SJ, Horton KW, Auron PE, Byers MG, Shows TB and Webb AC (1990) Chromosomal organization and localization of the human urokinase inhibitor gene: Perfect structural conservation with ovalbumin. Genomics 6: 159-167
27. Schleuning W-D, Medcaff RL, Hession C, Rothenbuhler R, Shaw A and Kruithof EKO (1987) Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells, Mol. Cell. Biol. 7: 4564-4567
28. Testa JE and Quigley JP (1990) The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Canc. Metast. Rev. 9: 353-367
29. Vermes I, Haanen C, Steffensnakken H and Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184: 39-51
30. Wong GHW, Elwell JH, Oberley L and Goeddel DV (1989) Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity to tumor necrosis factor. Cell 58: 923-931
31. Wun T-C and Reich E (1987) An inhibitor of plasminogen activation from human placenta. Punfication and characterization. J. Biol. Chem. 262. 3636-3653
32. Ye RD, Ahern SM, Le Beau MM, Lebo RV and Sadler JE (1989) Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin. J. Biol. Chem. 264: 5495-5502
33. Ye RD, Wun TC and Sadler JE (1987) cDNA cloning and expression in Eschericha coli of a plasminogen activator inhibitor from human placenta. J. Biol. Chem. 262: 3718-3725
34. Yuan Z-M, Huang Y, Kraeft S-K, Chen LB, Kharbanda S and Kufe D (1996) Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine Oncogene 13: 939-946
35. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM and Salvensen GS (1997) Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem 272: 7797-7800